{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:19:06Z","timestamp":1740143946342,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s11523-022-00923-9","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T05:02:47Z","timestamp":1667797367000},"page":"655-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies"],"prefix":"10.1007","volume":"17","author":[{"given":"Kyle","family":"Dunton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Vondeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Burn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby","family":"Paine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"923_CR1","unstructured":"Cancer Research UK. Breast cancer incidence by sex and country (UK 2016\u20132018). 2021. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer\/incidence-invasive#heading-Zero. Accessed 14 June 2022."},{"key":"923_CR2","unstructured":"Cancer Research UK. Proportion of cancer cases diagnosed by stage (stacked chart). 2022. https:\/\/crukcancerintelligence.shinyapps.io\/EarlyDiagnosis\/. Accessed 14 June 2022."},{"issue":"8","key":"923_CR3","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andr\u00e9 F, et al. 4th ESO\u2013ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29(8):1634\u201357.","journal-title":"Ann Oncol"},{"issue":"2","key":"923_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/jclinpath-2014-202571","volume":"68","author":"EA Rakha","year":"2015","unstructured":"Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, et al. Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol. 2015;68(2):93\u20139.","journal-title":"J Clin Pathol"},{"issue":"4","key":"923_CR5","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.2353\/ajpath.2010.090885","volume":"177","author":"FJ Esteva","year":"2010","unstructured":"Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010;177(4):1647\u201356. https:\/\/doi.org\/10.2353\/ajpath.2010.090885.","journal-title":"Am J Pathol"},{"issue":"5","key":"923_CR6","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1038\/bjc.1995.497","volume":"72","author":"S Archer","year":"1995","unstructured":"Archer S, Eliopoulos A, Spandidos D, Barnes D, Ellis I, Blamey R, et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer. 1995;72(5):1259.","journal-title":"Br J Cancer"},{"issue":"5","key":"923_CR7","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/sj.bjc.6604940","volume":"100","author":"SM Tovey","year":"2009","unstructured":"Tovey SM, Brown S, Doughty JC, Mallon EA, Cooke TG, Edwards J. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer. 2009;100(5):680\u20133. https:\/\/doi.org\/10.1038\/sj.bjc.6604940.","journal-title":"Br J Cancer"},{"key":"923_CR8","unstructured":"Cancer Research UK. Breast cancer mortality by sex and UK country. 2018. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer\/mortality#heading-Zero. Accessed 14 June 2022."},{"key":"923_CR9","unstructured":"The Transforming Cancer Services Team in partnership with Macmillan Cancer Support and NCRAS. Cancer Prevalence in England\u201421 year prevalence by demographic and geographic measures. Excel workbook. 2018. http:\/\/www.ncin.org.uk\/about_ncin\/releases. Accessed 14 June 2022."},{"key":"923_CR10","unstructured":"National Institute for Health and Care Excellence (NICE). Eribulin for treating locally advanced or metastatic breast cancer after two or more prior chemotherapy regimens [ID964]. Committee papers. 2016. https:\/\/www.nice.org.uk\/guidance\/ta423\/documents\/committee-papers. Accessed 14 June 2022."},{"issue":"5","key":"923_CR11","doi-asserted-by":"publisher","first-page":"V85","DOI":"10.1093\/annonc\/mdx365","volume":"28","author":"JA Roth","year":"2017","unstructured":"Roth JA, Mahtani R. Survival gains from advances in first-line systemic therapy for HER2-positive metastatic breast cancer in the US, 1995\u20132015. Ann Oncol. 2017;28(5):V85. https:\/\/doi.org\/10.1093\/annonc\/mdx365.","journal-title":"Ann Oncol"},{"key":"923_CR12","doi-asserted-by":"publisher","first-page":"175883591983351","DOI":"10.1177\/1758835919833519","volume":"11","author":"S Pernas","year":"2019","unstructured":"Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol. 2019;11:1758835919833519. https:\/\/doi.org\/10.1177\/1758835919833519.","journal-title":"Ther Adv Med Oncol."},{"key":"923_CR13","unstructured":"National Institute for Health and Care Excellence (NICE). TA423. Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens. 2016. https:\/\/www.nice.org.uk\/guidance\/TA423. Accessed 14 June 2022."},{"key":"923_CR14","unstructured":"National Institute for Health and Care Excellence (NICE). CG81. Advanced breast cancer: diagnosis and treatment. 2017. https:\/\/www.nice.org.uk\/guidance\/cg81\/resources\/advanced-breast-cancer-diagnosis-and-treatment-pdf-975683850181. Accessed 14 June 2022."},{"issue":"1","key":"923_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2217\/fon-2018-0324","volume":"15","author":"S Barni","year":"2019","unstructured":"Barni S, Livraghi L, Morritti M, Vici P, Michelotti A, Cinieri S, et al. Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers\u2013ESEMPiO study. Future Oncol. 2019;15(1):33\u201344.","journal-title":"Future Oncol"},{"issue":"25","key":"923_CR16","doi-asserted-by":"publisher","first-page":"3922","DOI":"10.1200\/jco.2009.25.8467","volume":"28","author":"J Cortes","year":"2010","unstructured":"Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roch\u00e9 H, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010;28(25):3922\u20138. https:\/\/doi.org\/10.1200\/jco.2009.25.8467.","journal-title":"J Clin Oncol"},{"issue":"9769","key":"923_CR17","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/s0140-6736(11)60070-6","volume":"377","author":"J Cortes","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377(9769):914\u201323. https:\/\/doi.org\/10.1016\/s0140-6736(11)60070-6.","journal-title":"Lancet"},{"issue":"5","key":"923_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.7150\/jca.8748","volume":"5","author":"T Gamucci","year":"2014","unstructured":"Gamucci T, Michelotti A, Pizzuti L, Mentuccia L, Landucci E, Sperduti I, et al. Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. J Cancer. 2014;5(5):320\u20137. https:\/\/doi.org\/10.7150\/jca.8748.","journal-title":"J Cancer"},{"issue":"7","key":"923_CR19","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a","volume":"92","author":"JL Blum","year":"2001","unstructured":"Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92(7):1759\u201368. https:\/\/doi.org\/10.1002\/1097-0142(20011001)92:7%3c1759::aid-cncr1691%3e3.0.co;2-a.","journal-title":"Cancer"},{"issue":"4","key":"923_CR20","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","volume":"40","author":"P Fumoleau","year":"2004","unstructured":"Fumoleau P, Largillier R, Clippe C, Di\u00e8ras V, Orfeuvre H, Lesimple T, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004;40(4):536\u201342. https:\/\/doi.org\/10.1016\/j.ejca.2003.11.007.","journal-title":"Eur J Cancer"},{"issue":"26","key":"923_CR21","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CE Geyer","year":"2006","unstructured":"Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733\u201343. https:\/\/doi.org\/10.1056\/NEJMoa064320.","journal-title":"N Engl J Med"},{"issue":"3","key":"923_CR22","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10549-007-9885-0","volume":"112","author":"D Cameron","year":"2008","unstructured":"Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533\u201343. https:\/\/doi.org\/10.1007\/s10549-007-9885-0.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"923_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1634\/theoncologist.2009-0181","volume":"15","author":"D Cameron","year":"2010","unstructured":"Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15(9):924.","journal-title":"Oncologist"},{"issue":"12","key":"923_CR24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41416-019-0618-z","volume":"121","author":"SH Sim","year":"2019","unstructured":"Sim SH, Park IH, Jung KH, Kim S-B, Ahn J-H, Lee K-H, et al. Randomised phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+ metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16). Br J Cancer. 2019;121(12):985\u201390.","journal-title":"Br J Cancer"},{"key":"923_CR25","unstructured":"European Medicines Agency (EMA). Enhertu, trastuzumab deruxtecan. 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/enhertu. Accessed 14 June 2022."},{"key":"923_CR26","unstructured":"Medicines and Healthcare Products Regulatory Agency (MHRA). Summary of product characteristics. Enhertu 100\u00a0mg powder. 2022. https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/e35c7ffebbb6b8fe24de65fa715f53d779836754. Accessed 14 June 2022."},{"issue":"3","key":"923_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","volume":"67","author":"T Nakada","year":"2019","unstructured":"Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody\u2013drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull. 2019;67(3):173\u201385.","journal-title":"Chem Pharm Bull"},{"issue":"3","key":"923_CR28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.annonc.2019.11.019","volume":"31","author":"A Yver","year":"2020","unstructured":"Yver A, Agatsuma T, Soria JC. The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers. Ann Oncol. 2020;31(3):430\u20134. https:\/\/doi.org\/10.1016\/j.annonc.2019.11.019.","journal-title":"Ann Oncol"},{"issue":"20","key":"923_CR29","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097\u2013108. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2822.","journal-title":"Clin Cancer Res"},{"key":"923_CR30","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.pharmthera.2017.07.013","volume":"181","author":"PA Trail","year":"2018","unstructured":"Trail PA, Dubowchik GM, Lowinger TB. Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design. Pharmacol Ther. 2018;181:126\u201342. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.07.013.","journal-title":"Pharmacol Ther"},{"issue":"7","key":"923_CR31","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"issue":"4_Supplement","key":"923_CR32","doi-asserted-by":"publisher","first-page":"PD3-06","DOI":"10.1158\/1538-7445.SABCS20-PD3-06","volume":"81","author":"S Modi","year":"2021","unstructured":"Modi S, Saura C, Yamashita T, Park H, Kim S-B, Tamura K, et al. PD3-06: updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer. Cancer Res. 2021;81(4_Supplement):PD3-06.","journal-title":"Cancer Res"},{"key":"923_CR33","unstructured":"National Institute for Health and Care Excellence (NICE). Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (TA704). 2021. https:\/\/www.nice.org.uk\/guidance\/TA704. Accessed 14 June 2022."},{"key":"923_CR34","unstructured":"National Institute for Health and Care Excellence (NICE). NICE draft guidance provides Cancer Drugs Fund first in Europe access to new treatment option for advanced breast cancer 2021. https:\/\/www.nice.org.uk\/news\/article\/nice-draft-guidance-provides-cancer-drugs-fund-first-in-europe-access-to-new-treatment-option-for-advanced-breast-cancer. Accessed 14 June 2022."},{"issue":"7\u20138","key":"923_CR35","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1159\/000488202","volume":"41","author":"S Lv","year":"2018","unstructured":"Lv S, Wang Y, Sun T, Wan D, Sheng L, Li W, et al. Overall survival benefit from trastuzumab-based treatment in HER2-positive metastatic breast cancer: a retrospective analysis. Oncol Res Treat. 2018;41(7\u20138):450\u20135.","journal-title":"Oncol Res Treat"},{"issue":"6","key":"923_CR36","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","volume":"18","author":"IE Krop","year":"2017","unstructured":"Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(17)30313-3.","journal-title":"Lancet Oncol"},{"key":"923_CR37","unstructured":"Office for National Statistics. National life tables: England and Wales. 2019. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesenglandandwalesreferencetables. Accessed 14 June 2022."},{"issue":"3","key":"923_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10549-016-3958-x","volume":"159","author":"QA Le","year":"2016","unstructured":"Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast Cancer Res Treat. 2016;159(3):565\u201373. https:\/\/doi.org\/10.1007\/s10549-016-3958-x.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"923_CR39","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13(5):509\u201318. https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00700.x.","journal-title":"Value Health."},{"key":"923_CR40","unstructured":"National Institute for Health and Care Excellence (NICE). TA786. Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies. 2022. https:\/\/www.nice.org.uk\/guidance\/ta786. Accessed 14 Sept 2022."},{"issue":"SUPPLEMENT 5","key":"923_CR41","doi-asserted-by":"publisher","first-page":"S485","DOI":"10.1016\/j.annonc.2021.08.562","volume":"32","author":"CS Manich","year":"2021","unstructured":"Manich CS, Modi S, Krop I, Park YH, Kim S, Tamura K, et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol. 2021;32(SUPPLEMENT 5):S485\u20136.","journal-title":"Ann Oncol"},{"key":"923_CR42","unstructured":"Clinicaltrials.gov. DS-8201a in pre-treated HER2 breast cancer that cannot be surgically removed or has spread [DESTINY-Breast02] (NCT03523585). 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03523585. Accessed 14 June 2022."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00923-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-022-00923-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-022-00923-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T09:42:05Z","timestamp":1669196525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-022-00923-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["923"],"URL":"https:\/\/doi.org\/10.1007\/s11523-022-00923-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"type":"print","value":"1776-2596"},{"type":"electronic","value":"1776-260X"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"5 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Daiichi Sankyo Europe GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AP received consultancy fees for the statistical analyses presented in this manuscript. EH, MP, and OB are employees of Source Health Economics, which received consultancy fees for the extrapolation of long-term outcomes presented in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No additional data or materials are available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"No code is available.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Statistical analyses were performed by AP. Extrapolation of long-term outcomes were performed by EH, MP, and OB. All authors commented on the manuscript, and read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}